BioWorld® - Medical Device Daily

BioWorld Industrial Biotechnology StatReport: Immediate and Comprehensive Industry Information
SUBSIDIARY OF: Groupe Novasep
PRINCIPAL INVESTORS: Rockwood
BUSINESS STRATEGY: We are a specialist in solving purification and separation needs for the life
science industry, from laboratory to large industrial production.
Our fields of activities include: Process and product development, systems
and APIs.
RESEARCH & DEVELOPMENT: Process modelling and optimisation (chromatography, crystallization,
membranes, adsorption, ion exchange, etc.)
Process development
Process integration (chromatography / adsorption / crystallization /
distillation-evaporation / membranes, etc.)
Custom purification of APIs and intermediates in clinical phase
Custom synthesis (gram to kilogram)
Purification of intermediates and APIs
Production of intermediates and APIs
Cytotoxic expertise
PRODUCTS ON MARKET: High, medium and low pressure Batch preparative chromatography in liquid
and supercritical phase
High, medium and low continuous chromatography
Adsorption and ion exchange
Membranes (micro, nano and ultrafiltration)
Evaporation and crystallization
november AG
KEY PERSONNEL: Dr. Wolf M. Bertling; CEO
Alexander G. Offer; CFO
Astrid Dickert; CFO
EMPLOYEES: 65 employees
Ulrich-Schalk-Str. 3
Erlangen 91056, Germany
Phone: +49 (0) 9131 750 88 0; Fax: +49 (0) 9131 750 88 99
Web: www.november.de
E-mail: info@november.de
HISTORY: Founded in 1996
Began biotech R&D in 1997
Holding since the end of 2003
FACILITIES: 1,800 sq. m. headquarters
1,300 sq. m. R&D facility (offices of R&D included)
500 sq. m. administration facility
STOCK-FINANCIAL HISTORY: Traded on the Frankfurt Stock Exchange--NBX
IPO--(4/00)
Traded in segment Prime Standard (since 03/03)
Revenue EUR5.586M (YE 04) compared to EUR4.424M (YE 03)
Net loss (YE 04) compared to (YE 03)
Loss per share (YE 04) compared to
(YE 03)
Average shares outstanding 7.468M (YE 04) compared to 6.860M (YE 03)
Total assets EUR27.682M (YE 04) compared to EUR28.646M (YE 03)
SUBSIDIARIES/DIVISIONS: identif GmbH
directif GmbH
responsif GmbH
PEQLAB Biotechnologie GmbH--51%
PRINCIPAL INVESTORS: Dr. Wolf M. Bertling--8.03%
Jupiter Technologie GmbH&Co. KGaA--10.31%
Copyright ©2006 AHC Media ® 283